It's About Time: Brolucizumab Extends Treatment Effect in Wet AMD

COMMENTARY

It's About Time: Brolucizumab Extends Treatment Effect in Wet AMD

Sophie J. Bakri, MD

Disclosures

December 12, 2019

0

Why do we need another drug for wet age-related macular degeneration (AMD)? There are two good reasons: efficacy and duration. Despite even monthly treatment, a large proportion of patients with wet AMD still have fluid on optical coherence tomography (OCT). The search has therefore continued for a more efficacious drug that also lasts longer in the eye.

Brolucizumab (Beovu), recently approved by the US Food and Drug Administration, may be the drug that meets these clinical needs. A single-chain antibody fragment that inhibits vascular endothelial growth factor (VEGF)-A, brolucizumab's molecular design has the opportunity to penetrate tissue better (being smaller in size) and have a higher molar concentration.

After the OPSREY phase 2 trial showed brolucizumab's safety and efficacy, the HAWK and HARRIER phase 3 trials were undertaken to assess whether it was noninferior to aflibercept. Patients with untreated AMD participating in the trials were randomly assigned to loading doses of brolucizumab (3 or 6 mg) or aflibercept (2 mg) at weeks 0, 4, and 8.

The trial design differed with what we are used to seeing with other AMD trials, in that it represented a real-world clinical situation. Patients in the aflibercept arms received injections every 8 weeks, whereas those in the brolucizumab arms were scheduled to receive injections every 8 or 12 weeks.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....